An important example is INDIGO (NCT04164901), an ongoing randomized phase III study of vorasidenib, a promising oral inhibitor of IDH1/2 mutations that has shown a 30.8% objective response rate in non-enhancing glioma patients (49). This evidence concerns the gene IDH1 and central nervous system cancer.